← Insider buys

BMY

Bristol-Myers Squibb Company · Healthcare

Insiders sold $2.3M of Bristol-Myers Squibb Company in the last 12 months and bought none

$0Bought, 12 mo
$2.3MSold, 12 mo
$125.6BMarket cap

BMY over the last year

No insider buys filed in this year

BMY after insider buys

3 months after each buy, from the first price a copier could get.

−7.6%Average
−12.4 ptsVs S&P 500
1 of 5Higher

5 buys since 2017 with 3 months of prices.

Congress

Members reported 63 trades in BMY since 2023.

Every filing

94 insider filings since 2016, newest first

BMYSell

Cristian Massacesi · EVP,Chief Med Offr,Head of Dev

$403K−25.0%Sep 10
BMYSell

Phil M Holzer · SVP and Controller

$34K−2.9%Aug 26
BMYSell

David Elkins V · EVP and CFO

$1.9M−16.0%Apr 2
BMYBuy

Samit Hirawat · EVP,Chief Med.Offr.,Drug Dev.

$202K+5.0%Apr 29
BMYBuy

Christopher S. Boerner · CEO

$110K+2.0%Feb 21
BMYBuy

Samit Hirawat · EVP,Chief Med.Offr.,Drug Dev.

$100K+3.0%Feb 19
BMYBuy

Samit Hirawat · EVP,Chief Med.Offr.,Drug Dev.

$100K+3.0%Nov 5
BMYSell

Phil M Holzer · SVP, Controller

$39K−6.0%Nov 5
BMYBuy

Christopher S. Boerner · CEO

$100K+2.0%Dec 7
BMYSell

Ann Powell · EVP, Chief HR

$1.1M−39.0%Aug 28
BMYSell

Robert M Plenge · EVP and Chief Research Officer

$45K−10.0%Aug 7
BMYSell

Rupert Vessey · EVP, Pres, Research

$3.4M−51.0%May 4
BMYSell

Giovanni Caforio · Board Chair, CEO

$17.9M−50.0%Feb 8
BMYSell

Ann Powell · EVP, Chief HR

$835K−33.0%Feb 8
BMYSell

Ann Powell · EVP, Chief HR

$1.3M−32.0%Nov 14
BMYSell

Rupert Vessey · EVP, Research, Early Dev.

$3.6M−44.0%Nov 9
BMYSell

Giovanni Caforio · Board Chair, CEO

$1.7M−5.0%Sep 22
BMYSell

Giovanni Caforio · Board Chair, CEO

$3.6M−9.0%Sep 16
BMYSell

David Elkins V · EVP and CFO

$9.6M−53.0%Sep 15
BMYSell

Ann Powell · EVP, Chief HR

$1.8M−33.0%Sep 15
BMYSell

Giovanni Caforio · Board Chair, CEO

$2.2M−5.0%Jun 14
BMYSell

Sandra Leung · EVP and General Counsel

$4.9M−14.0%Jun 7
BMYSell

Giovanni Caforio · Board Chair, CEO

$1.8M−4.0%Mar 23
BMYSell

Rupert Vessey · EVP, Research, Early Dev.

$5.2M−59.0%Mar 18
BMYSell

Karen Murphy Santiago · SVP, Controller

$455K−28.0%Mar 16
BMYSell

Christopher S. Boerner · EVP and Chief Commercial Officer

$2.0M−41.0%Mar 16
BMYSell

Giovanni Caforio · Board Chair, CEO

$2.0M−6.0%Feb 28
BMYSell

Rupert Vessey · EVP, Research, Early Dev.

$1.2M−37.0%Dec 17
BMYSell

Autenried Paul Von · EVP and CIO

$2.9M−45.0%Nov 24
BMYSell

Giovanni Caforio · Board Chair, CEO

$1.5M−5.0%Sep 22
BMYSell

David Elkins V · EVP and CFO

$6.7M−55.0%Aug 16
BMYSell

Giovanni Caforio · Chair and CEO

$1.4M−4.0%Aug 4
BMYSell

Ann Powell · EVP, Chief HR

$1.6M−33.0%Aug 4
BMYSell

Adam Dubow · SVP,ChiefCompliance, EthicsOff

$167K−14.0%Aug 3
BMYSell

Sandra Leung · EVP and General Counsel

$2.0M−6.0%Aug 3
BMYSell

Rupert Vessey · EVP, Research, Early Dev.

$10.8M−77.0%Aug 3
BMYSell

Autenried Paul Von · EVP and CIO

$1.7M−18.0%Aug 3
BMYSell

Joseph Eid · SVP,Head Glob. Medical Affairs

$73K−12.0%May 11
BMYSell

Louis S Schmukler · EVP,Pres,Glob.Prod., Supply

$979K−32.0%May 11
BMYSell

Adam Dubow · SVP,ChiefCompliance, EthicsOff

$200K−15.0%May 7
BMYSell

Rupert Vessey · EVP, Research, Early Dev.

$2.0M−40.0%May 7
BMYSell

Giovanni Caforio · Chair and CEO

$1.6M−5.0%Mar 24
BMYSell

Adam Dubow · SVP,ChiefCompliance, EthicsOff

$57K−5.0%Nov 25
BMYSell

Rupert Vessey · EVP, Research, Early Dev.

$823K−26.0%Nov 25
BMYSell

Autenried Paul Von · EVP and CIO

$1.3M−14.0%Nov 25
BMYSell

Rupert Vessey · EVP, Research, Early Dev.

$3.5M−53.0%Nov 23
BMYSell

Giovanni Caforio · Chair and CEO

$2.5M−8.0%Sep 2
BMYSell

Joseph Eid · SVP,Head Glob. Medical Affairs

$341K−68.0%Aug 19
BMYSell

Sandra Leung · EVP and General Counsel

$8.9M−24.0%Aug 17
BMYSell

Adam Dubow · SVP,ChiefCompliance, EthicsOff

$195K−16.0%May 26
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.